Welcome to our dedicated page for Immutep American Depositary Shares news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep American Depositary Shares stock.
Immutep Limited (NASDAQ: IMMP) is a globally active biotechnology company focusing on the development of innovative immunotherapy products for cancer and autoimmune diseases. Listed on both the Australian Stock Exchange and the Nasdaq Global Market in the U.S., Immutep is at the forefront of personalized bio-therapeutic treatment options.
At the core of Immutep's research and development is the LAG-3 immune control mechanism, crucial for the regulation of the T cell immune response. The company's flagship product, IMP321, a T cell immunostimulatory factor (APC activator), has completed Phase II clinical trials for cancer chemo-immunotherapy. This product is designed to enhance the body's immune response to cancer, providing a novel treatment option for patients.
In addition to IMP321, Immutep is advancing several other LAG-3 related products. These include IMP701, a blocking anti-LAG-3 antibody for cancer currently in Phase I clinical trials, and CVac, a personalized immunocellular therapeutic being investigated for the treatment of epithelial cancer. The development of these products is supported through partnerships with large pharmaceutical companies, aiming to accelerate the availability of these innovative treatments.
Immutep's operations are headquartered in Australia, with the majority of its revenue derived from product sales. The company remains committed to maximizing shareholder value through its technological expertise and robust pipeline of products.
For investors, Immutep represents a significant opportunity in the biotechnology sector, with its cutting-edge research and promising clinical advancements poised to make a substantial impact on cancer and autoimmune disease treatment.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has made significant advancements in its clinical development strategy for the quarter ending March 31, 2023. The company initiated the AIPAC-003 Phase II/III trial for eftilagimod alpha (efti) in HER2-negative and triple-negative metastatic breast cancer, with the first patient enrollment expected in Q2 2023. Positive final data from the TACTI-002 trial showed a 39% overall survival rate at 21 months for patients with second-line non-small cell lung cancer (NSCLC). The TACTI-003 trial reached 75% enrollment, and top-line results are anticipated in H2 2023. Furthermore, the INSIGHT-003 trial's expansion aims to evaluate a triple combination therapy in NSCLC. Immutep maintains a robust cash position of A$55.2 million, providing a runway until June 2024.